Kontafarma China Holdings (HKSE:01312) Inventories, Raw Materials & Components: HK$11.8 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kontafarma China Holdings Inventories, Raw Materials & Components?

Kontafarma China Holdings HKSE:01312 Inventories, Raw Materials & Components is HK$11.8 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Kontafarma China Holdings's inventories, raw materials & components for the quarter that ended in Dec. 2025 was HK$11.8 Mil.

Kontafarma China Holdings's quarterly raw materials declined from Dec. 2024 (HK$12.8 Mil) to Jun. 2025 (HK$0.0 Mil) but then increased from Jun. 2025 (HK$0.0 Mil) to Dec. 2025 (HK$11.8 Mil).

Kontafarma China Holdings's annual raw materials declined from Dec. 2023 (HK$13.0 Mil) to Dec. 2024 (HK$12.8 Mil) and declined from Dec. 2024 (HK$12.8 Mil) to Dec. 2025 (HK$11.8 Mil).

Kontafarma China Holdings Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Kontafarma China Holdings's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kontafarma China Holdings Inventories, Raw Materials & Components Chart

Kontafarma China Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.50 17.30 12.98 12.84 11.79

Kontafarma China Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.98 0.00 12.84 0.00 11.79

Kontafarma China Holdings Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of HK$11.8 Mil mean?
Kontafarma China Holdings (HKSE:01312) has a Inventories, Raw Materials & Components of HK$11.8 Mil as of Dec. 2025. Raw materials are the components a company uses for its main products. View historical data on Kontafarma China Holdings and its competitors.
Is Kontafarma China Holdings' Inventories, Raw Materials & Components too high?
Kontafarma China Holdings' current Inventories, Raw Materials & Components is HK$11.8 Mil.
How does Kontafarma China Holdings' Inventories, Raw Materials & Components compare to ZTS?
Kontafarma China Holdings' Inventories, Raw Materials & Components of HK$11.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Kontafarma China Holdings and its competitors. Kontafarma China Holdings's current Inventories, Raw Materials & Components is HK$11.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kontafarma China Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kontafarma China Holdings (HKSE:01312) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.03 — trading 27.5% below its estimated fair value. The current Inventories, Raw Materials & Components is HK$11.8 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Kontafarma China Holdings (HKSE:01312), the current Inventories, Raw Materials & Components is HK$11.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kontafarma China Holdings Business Description

Address 30 Harbour Road, Room 12A15-12A20, 12A Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG
Kontafarma China Holdings Ltd and its subsidiaries are principally engaged in the pharmaceutical and fitness business. The Group manufactures and sells prescription drugs, including chemical drugs, traditional Chinese medicine prescriptions, active pharmaceutical ingredients, and API intermediates in China, and operates fitness centres, provides fitness and health consultation services, and operates a franchise business for royalty fee income. Its segments are the pharmaceutical business, which generates maximum revenue, and the fitness business. The Group operates in Mainland China, Singapore, Taiwan, and other regions, with maximum revenue from Mainland China.